Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 3/20 | 0.43 |
| ▸ | ASPH | Q12797 | 3/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.42 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.42 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.42 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29537506 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL222146 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL31474567 | 0.85 | MRGPRX4 (0.53) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL20271506 | 0.76 | TRPV1 (0.58) | SMN1; SMN2MAPTPYGLPYGMTRPV1 | |
| SCHEMBL29838843 | 0.74 | NOS3 (0.52) | ALDH1A1MRGPRX4KMOALKBH5FTO | |
| SCHEMBL16094684 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL29537984 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL29537298 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL16094569 | 0.73 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2MRGPRX4KMO | |
| SCHEMBL2678073 | 0.72 | KMT2A (0.56) | KDM4EALDH1A1MRGPRX4NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4186906-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE1, WEE2 | KDM4E 2254/4885ALDH1A1 4238/4885SMN1; SMN2 4653/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | KDM4E 3586/4885ALDH1A1 4697/4885SMN1; SMN2 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.